Overview

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

Status:
Completed
Trial end date:
2020-07-28
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche